RxDoctor Payments Data

Eric Shives, MD

Family Medicine · Seneca Falls, NYNPI 1982751533

Payments from drug & device makers

$13,064in general payments, 2019–2025

Across 819 payments — averaging $15.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • GSK$1K
  • Pfizer$1K
  • AstraZeneca$1K
  • Novo Nordisk$898
  • Lilly USA, LLC$780
  • plus $6K from 44 others

What the payments were for

  • Food & beverage$13,054100%
  • Education$110%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,064 in reported general payments places this provider in the 95th percentile of 4,321 family medicine providers in New York.

See all family medicine providers in New York

Medicare billing

Part B allowed, 2024
$1,440
Medicare patients
45
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide137$185,990
OzempicSemaglutide87$121,384
JardianceEmpagliflozin81$118,547
Trelegy ElliptaFluticasone/Umeclidin/Vilanter107$95,638
MounjaroTirzepatide65$75,965
XareltoRivaroxaban80$73,780
EliquisApixaban51$70,468
RybelsusSemaglutide38$56,579
Breztri AerosphereBudesonide/Glycopyr/Formoterol27$45,833
SynjardyEmpagliflozin/Metformin Hcl25$39,021
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr50$27,488
Synjardy XrEmpagliflozin/Metformin Hcl24$26,675
VascepaIcosapent Ethyl25$25,187
LinzessLinaclotide31$25,166
KerendiaFinerenone22$24,052

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$780$261,955202 claims
Boehringer IngelheimJardiance, Synjardy, Synjardy Xr$743$184,243130 claims
Novo NordiskOzempic, Rybelsus$898$177,963125 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,406$123,125157 claims
Johnson & JohnsonXarelto$252$73,78080 claims
PfizerEliquis$1,358$70,46851 claims
AstraZenecaBreztri Aerosphere, Farxiga$1,306$61,06442 claims
AbbVieLinzess$1,411$25,16631 claims
BayerKerendia$389$24,05222 claims
MerckBelsomra$363$9,13220 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,321 family medicine providers in New York.

Other family medicine in Seneca Falls

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →